top of page

NCI-2022-08654

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer


This is a research study of a new treatment for breast cancer. The treatment is a combination of two drugs: OP-1250: This is a new drug that is being tested for the first time in humans. It is a type of drug called an estrogen receptor antagonist. This means that it blocks the effects of estrogen on cancer cells. Ribociclib or Alpelisib: These are two drugs that are already approved for the treatment of some types of breast cancer. They work by blocking different pathways that cancer cells use to grow and divide. The trial is being conducted in two parts: Part 1 (Dose Escalation): This part of the trial will enroll a small number of patients to find the safest dose of OP-1250. Part 2 (Expansion): Once a safe dose is found, more patients will be enrolled in the trial to see if the combination of OP-1250 and ribociclib or alpelisib is effective in treating breast cancer. The trial is only for patients with advanced or metastatic HR-positive, HER2-negative breast cancer. This means that the cancer has spread from where it started to other parts of the body, and it is positive for the estrogen and progesterone receptors but negative for the HER2 protein.


For more information about the trial, click the link below:

NCI-2022-08654

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2020-02981

Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Ca

NCI-2022-09871

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of

NCI-2022-02710

10551 A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-Mutant Tumors This research study is studying a new type of cancer treatment. The trea

Comments


bottom of page